1 / 17

E van der Ryst and M Westby Pfizer Global Research and Development, Sandwich, UK

Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials. E van der Ryst and M Westby Pfizer Global Research and Development, Sandwich, UK. 47th ICAAC Chicago, USA, September 17–20, 2007. MOTIVATE 1 and 2: Trial Design.

theta
Download Presentation

E van der Ryst and M Westby Pfizer Global Research and Development, Sandwich, UK

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global Research and Development, Sandwich, UK 47th ICAAC Chicago, USA, September 17–20, 2007

  2. MOTIVATE 1 and 2: Trial Design Randomization 1:2:2 MOTIVATE 1 N=601MOTIVATE 2 N=474 OBT* + placebo OBT* + maraviroc (150 mg† QD) OBT* + maraviroc (150 mg† BID) Screening(6 weeks) Plannedinterim analysis 0 24w 48w • Patient eligibility criteria: • R5HIV-1 infection • HIV-1RNA ≥5,000 copies/mL • Stable pre-study ARV regimen, or no ARVs for ≥ 4 weeks • Resistance to and/or ≥ 6 months’ experience with ≥ one ARVfrom three classes (≥ two for PIs) • Patients stratified by: • Enfuvirtide use in OBT • HIV-1RNA < and ≥100,000 copies/mL at screening * OBT = optimized background therapy of 3–6 ARVs (PK boosting doses of RTV not counted as an ARV) † Patients receiving a PI (except TPV) and/or delavirdine in their OBT received 150 mg dose of MVC, all other patients received 300 mg dose of MVC

  3. OBT alone (N=209) MVC QD + OBT (N=414) MVC BID + OBT (N=426) MOTIVATE 1 and 2: Summary of Week 24 Efficacy Results Includes all patients who received at least one dose of study medication P<0.001*Difference: +51(95% CI: 33, 69) P<0.001* Difference: +49(95% CI: 31, 67) P<0.0001* P<0.0001* Patients (%) Mean change from baselinein CD4 count (cells/mm3) HIV-1 RNA <50 copies/mL† Mean Change from Baseline in CD4 Count‡ * versus OBT alone† HIV-1 RNA value imputed as baseline if missing or if patient discontinued before 24 weeks‡Last observation carried forward MOTIVATE 1 & 2-Week 24 van der Ryst, et al. 4th IAS 2007; Poster WEPEB116LB

  4. R5* X4† NR/NP D/M*† Dual/mixed tropic virus population Only CCR5-tropic virus detected Only CXCR4-tropic virus detected Non-reportable/ non-phenotypable Characterization of Maraviroc Resistance in MOTIVATE 1 and MOTIVATE 2: Study Overview OBJECTIVE: To study changes in HIV-1 tropism in patients who experienced treatment failure in the MOTIVATE 1 and 2 studies MOTIVATE 1 and MOTIVATE 2 Phase 3 studies in treatment-experienced patients (N=1,075) Tropism determined for all patients at screening, baseline, and all visits where VL>500 c/mL (Trofile™ assay, Monogram Biosciences) Assessment of CD4 count at failure, time of failure, and occurrence of Category C events by tropism result * CCR5-using virus; †CXCR4-using virus

  5. Patients With a Change in Tropism Result from R5 at Screening to D/M at Baseline had a Lower Median CD4+ Count • Of the 1042 patients with R5 virus at screening, approximately 8% had a change in tropism result between screening and baseline to non-R5 virus, prior to a change in ARV regimen or administration of study drug • This subgroup had a lower median CD4+ count and higher mean HIV-1 RNA at screening MOTIVATE 1 & 2

  6. OBT alone MVC QD + OBT MVC BID + OBT Outcome of Patients with non-R5 Virus at Baseline (Week 24) Includes all patients who received at least one dose of study medication HIV-1 RNA <50 c/mL CD4+ Count Change Tropism result at baseline: D/M R5 Patients (%) N= 17 33 33 187 362 377 MOTIVATE 1 & 2-Week 24

  7. CD4+ Count Increase in Patients Failing Maraviroc is Greater Even in Patients With D/M or X4 Virus at Failure Data excludes patients who had no tropism result at time of failure* Includes patients with non-R5 tropism result at baseline MOTIVATE 1 & 2 Lalezari J et al. CROI 2007; Abstract 104bLB; Nelson M et al.CROI 2007; Abstract 104aLB

  8. Patients Failing Maraviroc With D/M or X4 Virus Fail Earlier Than Those Failing with R5 Virus Tropism result, Baseline → Treatment Failure: • Time to maraviroc treatment failure with a D/M or X4 virus was approximately 30 days shorter than for failure with R5 virus R5 → D/M or X4 R5 → R5 Patients (%) Early failure (≤ day 70) (N=82) Late failure (> day 70) (N=59) MOTIVATE 1 & 2

  9. No Association Between Category C Events and Treatment-emergent D/M or X4 Virus • The number of patients experiencing CDC Category C events in the study was low: 14 (6.7%) OBT alone, 26 (6.3%) MVC QD and 18 (4.2%) MVC BID • There was no evidence of an increased rate of Category C events in patients receiving maraviroc + OBT vs those receiving OBT alone despite the extended treatment duration on maraviroc1,2 • Only 5 patients with R5 virus at baseline who experienced a Category C event had D/M or X4 virus at the time of the event (3 on MVC QD, 1 on MVC BID, and 1 on OBT alone) • All 5 patients had a baseline CD4 count <20 cells/mm3 and were therefore at high risk of developing a Category C event • Category C events were therefore not associated with treatment-emergent CXCR4-using virus MOTIVATE 1 & 2 1. Lalezari J et al. CROI 2007; Abstract 104bLB; 2. Nelson M et al.CROI 2007; Abstract 104aLB

  10. Reversion to R5 after Cessation of Maraviroc Treatment • For maraviroc patients with D/M or X4 virus at treatment failure and with in-study off-drug (ISOD) follow-up data, virus in 68% of patients was R5 at last follow-up • Time of follow-up was significantly shorter for patients with D/M or X4 virus at their last study visit • Where follow-up >1 month, virus in 30 out of 31 patients reverted to R5 during ISOD follow-up MOTIVATE 1 & 2

  11. D D D R X X R R D D X R X D R D X D R D D R X X R D R X R D X X R D R X D D D X R X R R R X X X R D R D D D X X R R R Dual/mixed (D/M) tropism D D X R R R R R X R X X R X X R X X R X X X D R R X R R X D R R X X X X R X X X X R X X X R X R X R R X R D R X X R R X X D X X R R X R Viral Populations That May Exist Within a Patient A) Pure X4 R5 B) Mixed

  12. 500 400 300 200 100 0 -100 0 100 200 300 Example of a Patient With Treatment-emergent D/M Virus Treatment start Failure Treatment end Patient T6 R5 R5 DM DM DM DM DM DM R5 R5 6 5 4 HIV-1 RNA (log10 copies/mL) 3 CD4 Count (cells/mm3) 2 1 Time Since First Administration (Day) Lewis M et al. XVI International HIV Drug Resistance Workshop, June 2007, Abstract 56

  13. 500 400 300 200 100 0 -100 0 100 200 300 CXCR4-using env Clones Were Detected at Low Frequency in the Baseline Sample Patient T6 R5 R5 DM DM DM DM DM DM R5 R5 6 5 4 • CXCR4-using clones detected at baseline (7%) • No CCR5-tropic clones on treatment HIV-1 RNA (log10 copies/mL) 3 CD4 Count (cells/mm3) 2 1 Time Since First Administration (Day) Lewis M et al. XVI International HIV Drug Resistance Workshop, June 2007, Abstract 56

  14. R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R D D D D R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R X R R R R R R R R R R R R R R R R R R R R R R R R D D D D D D D R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R D X D D Selective Inhibition of R5 Viruses can Lead to a Change in Tropism Result to D/M or X4 • Trofile™ (like all resistance tests) measures relative proportions (not absolute amounts) of different viruses (Panel A) • Selective inhibition of a majority virus type, increases the sensitivity to detect the minor variant (Panel B) A B MVC R5 D/M

  15. Selective Inhibition of R5 Viruses Can Lead to a Change in Tropism Result to D/M or X4 • Maraviroc selectively inhibits R5 virus • If maraviroc is administered as part of a sub-optimal regimen, pre-existing low (undetected) levels of D/M or X4 virus will emerge as the dominant viral population • Since the D/M or X4 virus is pre-existing, time to failure is shorter than with R5 virus (where maraviroc resistance must be selected de novo) • Similar to the rapid outgrowth of pre-existing (archived) drug-resistant virus when failed ARV therapy is reinitiated after treatment interruption • After withdrawal of maraviroc, selective pressure on R5 virus is removed, allowing R5 virus to re-emerge as the dominant population • Reversion to R5 takes approximately 16 weeks, consistent with loss of 3TC1 or enfuvirtide2 resistance after withdrawal of these ARVs 1. Deeks S, et al. J Infect Dis2005; 192:1537-44. 2. Deeks et al. J Infect Dis 2007;195:387-91.

  16. Conclusions • Tropism changes are associated with MVC treatment failure • Patients failing MVC therapy had higher mean CD4+ count increases even in the context of emergence of D/M or X4 virus • Time to failure was shorter for patients failing with D/M or X4 virus vs R5 virus • Patients who failed MVC therapy with D/M or X4 virus reverted to an R5 virus tropism result after cessation of MVC therapy • There was no association between Category C events and treatment-emergent D/M or X4 virus • These data are consistent with the selective and reversible suppression of R5 virus during MVC therapy, resulting in detection of D/M or X4 virus at time of failure in two-thirds of failing patients

  17. Acknowledgments • Investigators and study site staff • Patients who participated in the study • Colleagues from Pfizer: Howard Mayer, James Goodrich, Irina Konourina, Margaret Tawadrous, Marilyn Lewis, Paul Simpson, Ayman Ayoub, Andrew Bullivant and John Sullivan

More Related